Clinical Trials Logo

Sarcoidosis, Pulmonary clinical trials

View clinical trials related to Sarcoidosis, Pulmonary.

Filter by:

NCT ID: NCT06205121 Recruiting - Clinical trials for Pulmonary Sarcoidosis

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

Start date: March 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.

NCT ID: NCT06169397 Not yet recruiting - Clinical trials for Pulmonary Sarcoidosis

An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

Start date: March 2024
Phase: Phase 2
Study type: Interventional

Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement

NCT ID: NCT06113991 Recruiting - Clinical trials for Pulmonary Sarcoidosis

Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis

BERYSARC
Start date: June 14, 2023
Phase:
Study type: Observational

Inhalation of beryllium can induce specific sensitization and diffuse pulmonary granulomatosis called chronic beryllium disease (CBD). The clinical, radiographic, and anatomopathological features of CBD are very similar to those of sarcoidosis, another granulomatosis, making its diagnosis difficult. In addition, the progression of CBD is poorly understood. The investigators hypothesis is that there are specific clinical, biological, anatomopathological, and radiological presentation specificities of CBD, as well as a worse prognosis compared to pulmonary sarcoidosis.

NCT ID: NCT05910554 Not yet recruiting - Clinical trials for Sarcoidosis, Pulmonary

Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis

MetforminTOP
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This is a double blinded, randomized, placebo controlled clinical trial of 40 participants with pulmonary sarcoidosis. Primary Objective: To assess the steroid-sparing efficacy and safety of oral metformin therapy in participants with confirmed progressive pulmonary sarcoidosis for participants with steroid dependent disease.

NCT ID: NCT05890729 Recruiting - Clinical trials for Pulmonary Sarcoidosis

A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

Start date: November 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis

NCT ID: NCT05841758 Not yet recruiting - Clinical trials for Sarcoidosis, Pulmonary

Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis

CAESAR
Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

Sarcoidosis is a systemic granulomatous disease of unknown aetiology, mainly affecting the lungs and lymphatics. It affects people worldwide (incidence, 4.7-64/100000; prevalence, 1-36/100000/year). Although it is most often a benign acute or subacute condition, sarcoidosis may progress to a disabling chronic disease in 25% of the cases, with severe complications in about 5%, such as lung fibrosis, cardiac or neurosarcoidosis, defacing lupus pernio or blindness due to uveitis. When indicated, corticosteroids (CS) are the mainstay of treatment. Due to the kinetics of granuloma resolution, the usual and quite 'dogmatic' duration of treatment is said to be one year, following four classical steps. The long-term use of CS is hindered by cumulative toxicity and efforts have to be made to taper them, as quickly as possible, to the lowest effective dose. A recent report mentioned 39% of the CS-treated patients requiring a steroid-sparing agent. Chloroquine (CQ) and hydroxychloroquine (HCQ) are anti-malarial drugs that have been used since the 1960's as steroidsparing agents on the basis of a landmark study by Siltzbach reporting their efficacy in 43 patients with skin and intrathoracic sarcoidosis. Subsequently, two small randomized controlled trials have shown significant and prolonged improvement on pulmonary symptoms. Only small case series/reports have shown CQ/HCQ efficacy on extra-pulmonary sarcoidosis with response rates ranging from 67 to 100%. Nevertheless, CQ/HCQ are daily used for skin, bone, and joint sarcoidosis, as well as hypercalcemia. Nowadays, HCQ is preferred over CQ because of a lower incidence of gastrointestinal and ocular adverse reactions, which can be minimized by close attention to the dosage and regular retinal examination. Its profile of safety is well-known since it has long been employed to treat systemic lupus erythematous or rheumatoid arthritis. Its action is thought to rely on its ability to accumulate in lysosomes of phagocytic cells, to affect antigen presentation and reduce pro-inflammatory cytokines. The investigator hypothesize that HCQ may be an efficacious add-on therapy for extra-pulmonary sarcoidosis leading to a significant steroid-sparing effect.

NCT ID: NCT05811962 Completed - Clinical trials for Sarcoidosis, Pulmonary

The Diagnostic and Prognostic Role of SAA in Intrathoracic Sarcoidosis

SARCO
Start date: January 1, 2014
Phase:
Study type: Observational

The goal of this observational study is to elucidate the role of serum amyloid A (SAA) in the diagnosis and follow-up of sarcoidosis, including its prognostic value. The main questions it aims to answer are: - Whether, at the time of diagnosis, SAA is in correlation with other serum markers of granulomatous inflammation, interstitial disease and pulmonary fibrosis, lung function and radiologic characteristics of intrathoracic sarcoidosis, - Whether increased serum concentrations of SAA at the time of diagnosis act as a prognostic marker of progressive granulomatous inflammation and pulmonary interstitial disease. Patients will undergo standard diagnostic procedures for intrathoracic sarcoidosis, according to WASOG (World association of sarcoidosis and other granulomatous disorders) criteria. Two additional vials of blood will be taken at diagnosis and one vial at follow-up for serum processing and biomarker analysis. Healthy blood donors will represent our group of healthy controls.

NCT ID: NCT05759221 Recruiting - Clinical trials for Sarcoidosis, Pulmonary

Peripheral Airway Biopsy in Sarcoidosis

Sopranos
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Airway involvement in sarcoidosis was demonstrated in a meaningful, albeit variable, proportion of patients through biopsy of the central, endoscopically visible airways. Ideally, biopsy of peripheral airways, nowadays possible with the introduction in the market of ultrathin bronchoscopes, might be associated with an increased diagnostic yield for the detection of granulomas.

NCT ID: NCT05746039 Recruiting - Obesity Clinical Trials

Feasibility of Semaglutide in Advanced Lung Disease

Start date: January 29, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question[s] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.

NCT ID: NCT05567133 Recruiting - Clinical trials for Sarcoidosis, Pulmonary

Risk Indicators of Sarcoidosis Evolution-Unified Protocol

RISE-UP
Start date: January 10, 2023
Phase:
Study type: Observational

The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.